Our Authors
Eisai Co., Ld. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. For more information visit our Company Page on Oncology News or our Website.1 Articles
Professor Andrew Scott is a nuclear medicine physician and a scientist and researcher, who sees oncology patients as part of therapeutics development and clinical trials. He is the Director of Molecular Imaging and Therapy, Austin Health where his team are pioneering new imaging technologies that promise to transform the diagnosis of multiple cancers. In addition to his work at Austin Health and academic roles, he leads the Tumour Targeting Laboratory in the Olivia Newton-John Cancer Research Institute. He has been working in the area of molecular imaging and new diagnostics and therapeutics for over 20 years.1 Articles
Creating outstanding digital resources tailored for the Australian Oncology community, including independent news and a dedicated job portal.1 Articles
The leading lung cancer & mesothelioma clinical trials group in Australia & New Zealand1 Articles
Associate Professor Caroline Ford is a cancer researcher within the School of Women's and Children's Health at the Lowy Cancer Research Centre. After completing her PhD at UNSW on the topic of oncogenic viruses, A/Prof Ford undertook two international postdoctoral appointments in cancer research. Her first postdoctoral research appointment was at the University of Toronto, Canada and the second appointment was at Lund University, Sweden. She returned to UNSW in late 2009 funded by an NHMRC CJ Martin Fellowship and established her research group within the Adult Cancer Program. A/Prof Ford leads the Gynaecological Cancer Research Group (GCRG), which aims to understand why gynaecological cancers develop, how and why they spread throughout the body, and how best to treat them. “Gynaecological cancer” encompasses all cancers of the female reproductive system, though our current research focuses on ovarian and endometrial cancer. The GCRG works closely with clinical staff at the Royal Hospital for Women, and has a number of studies involving sample collection from patients. Current projects include the development of an early detection test for ovarian cancer, and the identification of key targets for anti-metastatic therapies in ovarian and endometrial cancer. We are also investigating properties of ascites, a fluid build-up associated with aggressive disease. A/Prof Ford is an experienced university lecturer, convening courses on medical research, cancer pathology and personalised medicine, including Australia's first MOOC (Massive Open Online Course) on Personalised Medicine. She has completed a Graduate Certificate in University Learning & Teaching, and is passionate about science communication and enhancing the health literacy of the wider community. In 2017 she was named as an inaugural ‘Superstar of STEM’ by Science & Technology Australia. In 2018 she received the Women's Agenda Award for Female Leader in Science, Medicine & Health.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis and help patients with infertility, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. For more information visit our Company Page on Oncology News or our Website.
Dr Bourne was also one of the first Urologists in Queensland to establish Brachytherapy treatment for prostate cancer at Greenslopes Private Hospital and the first and currently the only one to offer this treatment at the John Flynn Private Hospital Gold Coast. Dr Bourne Established his private practice in 2000 providing a comprehensive range of urological services at the John Flynn Private Hospital and the Tweed Heads and Murwillumbah District Hospital. Dr Bourne also provides education and training to the urological registrar’s at the Tweed Heads and Murwillumbah District Hospital.